[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100594007":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":31,"centralContacts":36,"locations":42,"responsibleParty":62,"collaborators":26,"id":65,"slug":66,"hasResults":67,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":26,"eligibilityCriteria":71,"healthyVolunteers":67,"sex":72,"minAge":73,"maxAge":26,"enrollmentInfo":74,"targetDuration":26,"studyType":77,"phases":78,"briefSummary":80,"conditions":81,"keywords":83,"overallStatus":88,"whyStopped":26,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":98},{"fullName":5,"class":6},"Chinese SLE Treatment And Research Group","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Deucravacitinib treatment group","EXPERIMENTAL","Patients randomly assigned to the deucravacitinib treatment group are required to take the deucravacitinib tablets 6mg orally once daily on an empty stomach or after a meal during D1-D168, and orally take the study drug deucravacitinib with warm water. It is forbidden to drink water from 1 h before administration to 1 h after administration (except for administration of water) and fasting within 1 h after administration. Continuous treatment for 168 days or subject discontinuation criteria were met. The time of dose administration is called \"0\" hour. Subjects who miss a study medication on one day are not allowed to take a supplement to compensate but should take the next dose.",[13],"Drug: Deucravacitinib",{"label":15,"type":16,"description":17,"interventionNames":18},"Adalimumab treatment group","ACTIVE_COMPARATOR","Participants assigned to the adalimumab treatment group receive adalimumab 40mg by subcutaneous injection every 2 weeks during D1-D168. Adalimumab is administered for 24 weeks unless the discontinuation criteria are met.",[19],"Drug: Adalimumab",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Deucravacitinib","Deucravacitinib is a new, oral, selective, allosteric inhibitor of TYK2. It was first approved in the United States on 09-Sep-2022 for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Adalimumab","TNFα inhibitors have already been used in TAK treatment. Several retrospective studies have demonstrated the treatment effects of these agents in patients with TAK, including disease remission, GC tapering and vascular inflammation control. According to the ACR and EULAR guidelines, TNFis are recommended to be considered in cases of relapsing or refractory TAK. These agents (including adalimumab) are the most frequently analyzed therapeutic modalities in recent studies of TAK.",[15],[32],{"name":33,"affiliation":34,"role":35},"Xinping Tian, MD","Peking Unione Mdecial College Hospital","PRINCIPAL_INVESTIGATOR",[37],{"name":38,"role":39,"phone":40,"phoneExt":26,"email":41},"Shangyi Jin, MD","CONTACT","86+13671049688","jinshangyi@pumch.cn",[43],{"facility":44,"status":26,"city":45,"state":26,"zip":46,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"Peking Union Medical College Hospital","Beijing","100730","China","CN",{"type":50,"coordinates":51},"Point",[52,53],116.39723,39.9075,{"lat":53,"lon":52},[56,59,61],{"name":33,"role":39,"phone":57,"phoneExt":26,"email":58},"86-13691165939","tianxp6@126.com",{"name":38,"role":39,"phone":60,"phoneExt":26,"email":41},"86-13671049688",{"name":33,"role":35,"phone":26,"phoneExt":26,"email":26},{"type":35,"investigatorFullName":63,"investigatorTitle":64,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"Xinping Tian","Professor of Medicine","100594007","phase-4-the-efficacy-and-safety-of-deucravacitinib-in-takayasus-arteritis-100594007",false,"NCT07013838","The Efficacy and Safety of Deucravacitinib in Takayasu's Arteritis","Comparison of Deucravacitinib and Adalimumab for the Treatment of Relapsed Takayasu's Arteritis: The TYK-TAK Trial","Inclusion Criteria:\n\n* Participants are eligible to be included in the study only if all of the following criteria apply:\n\n  1. Signed Written Informed Consent\n\n     1. Participants fully understand the purpose, nature, method, and possible adverse reactions of the study, willing to consent to the trial and follow study protocol and sign informed consent.\n     2. Participants must have signed an Institutional Review Board (IRB)\u002FIndependent Ethics Committee (IEC)-approved written informed consent form (ICF) in accordance with regulatory, local, and institutional guidelines. This ICF must be obtained before performing any protocol related procedures that are not part of normal patient care.\n  2. Type of Participant and Target Disease Characteristics\n\n     1. Adult patients (aged 18 or older) fulfilling the 2022 ACR\u002FEULAR classification criteria for TAK.\n     2. Persistence of active disease or relapse despite treatment with GCs combined with a conventional synthetic or biologics immunosuppressive agent other than TNFi.\n     3. Active vasculitis by reader interpretation of FDG-PET at enrollment (by the same reader).\n  3. Reproductive Status The investigator or designee shall counsel women of childbearing potential (WOCBP) and male participants who are sexually active with WOCBP on the importance of pregnancy prevention and the implications of an unexpected pregnancy.\n\nWOCBP must have a negative highly sensitive specify: urine or serum as required by local regulations pregnancy test (minimum sensitivity 25 IU\u002FL or equivalent units of human chorionic gonadotropin) within 24 hours prior to the start of study intervention.\n\nA female is eligible to participate if she is not pregnant or breastfeeding and at least 1 of the following conditions applies:\n\nIs not a WOCBP OR Is a WOCBP and using a contraceptive method that is highly effective (with a failure rate of \\\u003C 1% per year) during the intervention period and for at least 5 half-lives after product administration and agrees not to donate eggs (ova, oocytes) for the purpose of reproduction for the same period.\n\nWOCBP and male participants who are sexually active with WOCBP must agree to follow instructions for method(s) of contraception.\n\nExclusion Criteria:\n\n* Participants are excluded from the study if any of the following criteria apply:\n\n  1. Medical Conditions\n\n     1. Severe disease from TAK for which urgent treatment with interventional procedures or bypass surgery is considered necessary\n     2. Critical organ involvement of TAK, such as myocardial or coronary artery involvement, or cerebral ischemia\n     3. Active hepatitis B or C virus infection, active tuberculosis infection\n     4. Malignancy in the past 5 years (with the exception of fully excised non-melanoma skin cancer or cervical carcinoma in situ)\n  2. Physical and Laboratory Test Findings\n\n     1. Serum liver enzyme tests 3 times higher than the upper limits of normal range\n     2. Estimated glomerular filtration rate ≤ 30 ml\u002Fminute\n  3. Other Exclusion Criteria\n\n     1. Females who are pregnant\n     2. Ever treated with TNFi (including adalimumab) and discontinued due to inadequate response or intolerance.\n     3. Any other sound medical, psychiatric, and\u002For social reason as determined by the investigator","ALL","18 Years",{"count":75,"type":76},50,"ESTIMATED","INTERVENTIONAL",[79],"PHASE4","This is a 24-week, single-center, randomized, open-label trial conducted by Peking Union Medical College Hospital. The aim of this study is to assess the efficacy and safety of deucravacitinib in adult patients with relapsing TAK in comparison to patients treated with TNF inhibitor (TNFi), the most well-recognized therapeutic choice of non-glucocorticoid immunosuppressive for patients with relapsed or refractory TAK.",[82],"Takayasu Arteritis (TAK)",[23,28,84,85,86,87],"Relapsed","Efficacy","Safety","Takayasu arteritis","NOT_YET_RECRUITING","2025-06-06",{"date":91,"type":92},"2025-06-10","ACTUAL",{"date":94,"type":76},"2025-06-15",{"date":96,"type":76},"2028-03-31",{"name":5,"class":6},1]